Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
- DOI
- 10.1002/cpdd.1153
- Published
- 2022-08-27
- Container
- Clinical Pharmacology in Drug Development
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/cpdd.1153,
title = {Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors},
author = {Shringi Sharma and Xavier Pepin and Harini Burri and Lianqing Zheng and Nataliya Kuptsova‐Clarkson and Anouk de Jong and Ting Yu and Holly L. MacArthur and Michal Majewski and John C. Byrd and Richard R. Furman and Joseph A. Ware and James Mann and David Ramies and Veerendra Munugalavadla and Louise Sheridan and Helen Tomkinson},
year = {2022},
journal = {Clinical Pharmacology in Drug Development},
doi = {10.1002/cpdd.1153},
url = {https://doi.org/10.1002/cpdd.1153}
}RIS
TY - JOUR TI - Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors AU - Shringi Sharma AU - Xavier Pepin AU - Harini Burri AU - Lianqing Zheng AU - Nataliya Kuptsova‐Clarkson AU - Anouk de Jong AU - Ting Yu AU - Holly L. MacArthur AU - Michal Majewski AU - John C. Byrd AU - Richard R. Furman AU - Joseph A. Ware AU - James Mann AU - David Ramies AU - Veerendra Munugalavadla AU - Louise Sheridan AU - Helen Tomkinson PY - 2022 JO - Clinical Pharmacology in Drug Development DO - 10.1002/cpdd.1153 UR - https://doi.org/10.1002/cpdd.1153 ER -
APA
Sharma, S., Pepin, X., Burri, H., Zheng, L., Kuptsova‐Clarkson, N., Jong, A. D., Yu, T., MacArthur, H. L., Majewski, M., Byrd, J. C., Furman, R. R., Ware, J. A., Mann, J., Ramies, D., Munugalavadla, V., Sheridan, L., & Tomkinson, H. (2022). Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1153
Source records
- crossref · retrieved 2026-09-27T03:34:20.788Z